Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice

Cosimo, Serena Di; Trama, Annalisa; Merlo, Ivan; Minicozzi, Pamela; Tarantini, Luigi; Apolone, Giovanni; Corrao, Giovanni; Franchi, Matteo

doi:10.1093/annonc/mdz265

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Riscul major al complicațiilor trombotice a fost evaluat în perioada inițială de la stabilirea diagnosticului de cancer, maximum fiind constatat în primele 3-6 luni [33]. Incidența evenimentelor trombotice la un pacient cu tumoare malignă este mai mare în primele 90 de zile de la stabilirea diagnosticului [34,35]. Aceste evenimente ar putea fi explicate prin faptul că inițial se constată o activitate crescută a tumorii maligne, iar apoi se asociază chimioterapia, care amplifică șansele dezvoltării evenimentelor tromboembolice [33,34,35].…”

Section: Factorii De Risc Individuali Ai Pacientuluiunclassified

“…Incidența evenimentelor trombotice la un pacient cu tumoare malignă este mai mare în primele 90 de zile de la stabilirea diagnosticului [34,35]. Aceste evenimente ar putea fi explicate prin faptul că inițial se constată o activitate crescută a tumorii maligne, iar apoi se asociază chimioterapia, care amplifică șansele dezvoltării evenimentelor tromboembolice [33,34,35]. Diagnosticul de TEV în primul an al cancerului constituie un predictor major de deces.…”

Section: Factorii De Risc Individuali Ai Pacientuluiunclassified

See 1 more Smart Citation

Management of the risk of thromboembolic complications in oncology

Buruiana¹

2021

SPEMM

View full text Add to dashboard Cite

Oncological disease is a hypercoagulable state with an associated increased risk of venous thromboembolism and is associated with high rates of recurrence and mortality. For those reasons, the prevention of cancer-associated thrombosis is of paramount importance. Knowledge of thromboembolic risk factors in oncology is absolutely necessary for the evaluation of the individual risk-benefit ratio of prophylaxis. The aim of this paper is to elucidate the risk factors of thromboembolic complications in cancer patients. In order to achieve the set aim, the medical scientifi c publications from the GoogleSearch database, PubMed, Z-library, NCIB, Medscape, Hinari, were searched for the keywords: „cancer-associated thrombosis”, „cancer”, „risk factor”. The information was systematized, highlighting the risk factors for thromboembolic complications in patients with cancer.

show abstract

Section: Factorii De Risc Individuali Ai Pacientuluiunclassified

Management of the risk of thromboembolic complications in oncology

Buruiana¹

2021

SPEMM

View full text Add to dashboard Cite

show abstract

Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison

Johnson,

Stoffel,

Schwitter

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose Common side effects of taxane chemotherapy are nail toxicity and peripheral neuropathy (CIPN) causing severe impact on the quality of life. Different methods of cryotherapy to prevent these side effects have been tested. We investigated the use of machine-controlled cooling of hands and feet to reduce nail toxicity and CIPN in patients receiving taxane chemotherapy. Methods Patients receiving Docetaxel (planned dose $$\ge$$ ≥ 300 mg/m2) or Paclitaxel (planned dose $$\ge$$ ≥ 720 mg/m2$$-$$ - ) in the adjuvant or palliative setting of different cancers were included. The dominant hand and foot were cooled to approximately 10 °C using the Hilotherapy machine. The contralateral hand and foot were used as intrapatient comparison. The primary endpoint was the occurrence of any CIPN due to paclitaxel or nail toxicity due to Docetaxel. Both the intention to treat population (ITT) and the per protocol population (PPP) were analyzed. Results A total of 69 patients, 21 treated with Docetaxel and 48 with Paclitaxel, were included at our centre between 08/2020 and 08/2022. Nail toxicity due to Docetaxel was overall not significantly improved by cooling in the ITT or PPP but a significant benefit across visits was found for the ITT. CIPN due to Paclitaxel was numerically better in the ITT and significantly better in the PPP. A significant benefit of cooling on CIPN occurrence across visits was found for the ITT and the PPP. Cooling was very well tolerated. Conclusion Cooling of hands and feet has a clinically meaningful impact on reducing occurrence of CIPN and nail toxicity on treatment with taxanes. Effects are more significant over time and are dose dependent. Trial registration number. 2020–00381. Date of registration. 24th February 2020.

show abstract

Long term follow-up (F/U) report of symptomatic cardiac events (SCEs) in 2,809 breast cancer (BC) patients (pts) treated with adjuvant trastuzumab (T) in real world (RW) practice

Cited by 2 publications

References 0 publications

Management of the risk of thromboembolic complications in oncology

Management of the risk of thromboembolic complications in oncology

Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison

Contact Info

Product

Resources

About